Business Segments · Subtotal

Oncology & Multispecialty — Subtotal

McKesson Oncology & Multispecialty — Subtotal decreased by 8.4% to $304.00M in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ3 2024
Last reportedQ4 2025

How to read this metric

An increase indicates growth in the segment's operational scale or profitability, while a decrease signals a contraction or margin pressure.

Detailed definition

Represents the aggregate financial performance or operational sub-total for the Oncology and Multispecialty segment befo...

Peer comparison

Comparable to 'Segment Operating Profit' or 'Segment Revenue' sub-totals reported by peer healthcare distribution companies.

Metric ID: mck_segment_oncology_multispecialty_subtotal

Historical Data

4 periods
 Q3 '24Q4 '24Q3 '25Q4 '25
Value$200.00M$202.00M$332.00M$304.00M
QoQ Change—+1.0%+64.4%-8.4%
YoY Change——+66.0%+50.5%
Range$200.00M – $332.00M
Avg YoY Growth+58.2%
Median YoY Growth+58.2%

Similar Metrics at Other Companies

Gilead Sciences logo
Gilead SciencesGILDView metric
Johnson & Johnson logo
Johnson & JohnsonJNJView metric
Stryker logo
StrykerSYKView metric
Boston Scientific logo
Boston ScientificBSXView metric
Medtronic logo
MedtronicMDTView metric
Medtronic logo
MedtronicMDTView metric

Frequently Asked Questions

What is McKesson's oncology & multispecialty — subtotal?
McKesson (MCK) reported oncology & multispecialty — subtotal of $304.00M in Q4 2025.
What does oncology & multispecialty — subtotal mean?
The combined financial sub-total for the Oncology and Multispecialty business segment.